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Only One Fifth of the Sudden Cardiac Arrest 
Victims in the Community are Eligible for a Primary 
Prevention ICD Before the Event, but Among These,  
a Small Proportion (13%) are Actually Implanted
According to data from the Oregon Sudden Unexpected 
Death study, among 2093 victims of sudden cardiac arrest 
(SCA) over a decade, of 448 having information about left 
ventricular ejection fraction (LVEF), 92 (20.5%) were eligible 
for primary ICD implantation, 304 (67.9%) were ineligible 
because of LVEF>35%, & the remainder (52, 11.6%) had 
LVEF ≤35% but were ineligible on the basis of clinical criteria. 
Among eligible subjects, only 12 (13%) received a primary 
ICD. Compared with recipients, ICD nonrecipients were 
older (age at LVEF assessment, 67.1±13.6 vs 58.5±14.8 years, 
P=0.05), with 20% aged ≥80 years (vs 0% among recipients, 
P=NS). Additionally, a subgroup (26%) had either a clinical 
history of dementia or were undergoing chronic dialysis. The 
authors concluded that only one fifth of the SCA cases in the 
community were eligible for a primary prevention ICD before 
the event, but among these, a small proportion (13%) were 
actually implanted. Although older age and comorbidity may 
explain nondeployment in a subgroup of these cases, other 
determinants such as socioeconomic factors, health insurance, 
patient preference, and clinical practice patterns may play a 
role (Narayanan K, et al, Circulation 2013;128:1733-1738).
Appropriate ICD Therapies over 10 Years are More 
Prevalent in Symptomatic Brugada Syndrome (19-48%) 
but Still Occur in Asymptomatic Patients (12%)
A total of 378 patients (310 men; aged 46±13 years) with a 
type 1 Brugada ECG pattern were implanted with an implant-
able cardioverter-defibrillator-ICD; 31 for aborted sudden 
cardiac arrest, 181 for syncope, and 166 asymptomatic. During 
a mean follow-up of 77±42 months for 363 patients, 7 patients 
(2%) died (1 as a result of an inappropriate shock), and 46 
patients (12%) had appropriate device therapy (5±5 shocks 
per patient). Appropriate device therapy rates at 10 years were 
48% for patients whose ICD indication was aborted sudden 
cardiac arrest, 19% for those with syncope, and 12% for the 
asymptomatic patients. At 10 years, rates of inappropriate 
shock and lead failure were 37% and 29%, respectively. Inap-
propriate shock occurred in 91 patients (24%) because of lead 
failure (n=38), supraventricular tachycardia (n=20), T-wave 
oversensing (n=14), or sinus tachycardia (n=12). Reduced 
inappropriate shocks were noted with introduction of remote 
monitoring, programming a high single ventricular fibrillation 
zone (>210–220 bpm), and a long detection time. The authors 
concluded that appropriate therapies are more prevalent in 
symptomatic Brugada syndrome but are not insignificant in 
asymptomatic patients (1%/y). Optimal ICD programming 
and remote monitoring dramatically reduce inappropriate 
shocks. However, lead failure remains a major problem in this 
population (Sacher F et al, Circulation 2013;128: 1739-1747).
Complex Antithrombotic Therapy Prescribed to 
Elderly Patients Increases the Risk of Gastrointestinal 
Bleeding
Among 78,133 veterans (98.6% white; mean age 72.3±7.7), 
64% were prescribed aspirin(ASA)-antiplatelet and antico-
agulant-antiplatelet and 6% were prescribed triple therapy 
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(anticoagulant-antiplatelet-ASA). The incidence of upper 
gastro-intestinal (GI) bleeding was 20.1/1000 patient-years, 
and the incidence of lower GI bleeding was 70.1/1000 patient-
years. ASA-anticoagulant and triple therapy were associated 
with the highest incidence of transfusion and hospitalization. 
A 40%-60% increased risk of upper GI bleeding was observed 
with all strategies. Lower GI bleeding was 30% higher with 
anticoagulant-antiplatelet, and transfusion increased with 
ASA-anticoagulant (hazard ratio-HR, 6.1) and triple therapy 
(HR, 5.0). Increased risk of hospitalization was noted with all 
strategies. The number needed to harm for upper or lower GI 
bleeding ranged from 52-65 & 15-23, respectively. The number 
needed to harm for hospitalization was 39 (anticoagulant-
antiplatelet), 34 (ASA-anticoagulant), 67 (ASA-antiplatelet), 
and 45 (triple therapy) patients. The authors concluded that 
among elderly patients, complex antithrombotic therapy-related 
lower and upper GI bleeding events are clinically relevant 
risks resulting in increased hospitalizations and transfusions 
(Abraham NS, et al, Circulation 2013;128: 1869-1877).
POST Trial: Negative Results for Ischemic 
Postconditioning During Primary PCI
In the POST (Postconditioning on Myocardial Reperfusion 
in Patients With STEMI) trial, a total of 700 patients undergoing 
primary percutaneous coronary intervention (PCI) for ST–el-
evation myocardial infarction (STEMI) within 12 hours after 
symptom onset were randomly assigned to the conventional 
primary PCI group or to the postconditioning group (balloon 
positioned at the culprit lesion was inflated 4 times for 1 min 
with low pressure inflations at <6 atm, each separated by 1 min 
of deflation). Complete ST resolution occurred in 40.5% of 
patients in the post-conditioning group and 41.5% of patients 
in the conventional PCI group (P=NS). The rate of myocardial 
blush grade of 0 or 1 and the rate of major adverse cardiac 
events (a composite of death, MI, severe heart failure, or stent 
thrombosis) at 30 days did not differ significantly between the 
postconditioning group and the conventional PCI group (17.2% 
vs 22.4% and 4.3% vs 3.7%, respectively; P=NS). The authors 
concluded that ischemic postconditioning did not improve 
myocardial reperfusion in patients with STEMI undergoing 
primary PCI (Hahn J-Y, Circulation 2013;128:1889-1896).
Patients With Normal Flow/Low Gradient Severe 
Aortic Stenosis With Preserved Ejection Fraction Have 
Favorable Survival With Medical Management, and the 
Impact of Surgery on Survival is Neutral
Among 1704 severe aortic stenosis (AS) patients with aortic 
valve area <1 cm2 and preserved ejection fraction (≥50%), 
those with normal flow (≥35mL/m2)/low gradient (<40 mm Hg) 
(n=352, 21%) had favorable survival with medical manage-
ment (2-year estimate, 82% vs 67% in normal flow/high grade; 
P<0.0001). Low flow/low gradient severe AS (n=53, 3%) was 
characterized by lower ejection fraction, more prevalent atrial 
fibrillation and heart failure, reduced arterial compliance, and 
reduced survival (2-year estimate, 60% vs 82% in normal flow/
high gradient; P<0.001). In multivariable analysis, the low flow 
/low gradient pattern was the strongest predictor of mortality 
(hazard ratio-HR, 3.26; P<0.001 vs normal flow/low gradient). 
Aortic valve replacement was associated with a 69% mortality 
reduction (HR, 0.31; P<0.0001) in low flow/low gradient and 
normal flow/high gradient, with no survival benefit associated 
with aortic valve replacement in normal flow/low gradient and 
low flow/ high gradient. The authors concluded that normal 
flow/low gradient severe AS with preserved ejection fraction 
exhibits favorable survival with medical management, and the 
impact of aortic valve replacement on survival was neutral. Low 
flow/low gradient severe AS is characterized by a high preva-
lence of atrial fibrillation, heart failure, and reduced survival, 
and aortic valve replacement was associated with improved 
survival (Eleid MF, et al, Circulation 2013;128:1781-1789).
Similar Benefit from TAVI of Patients With Low-Flow, 
Low-Gradient, Severe AS and either Normal or Low 
Ejection Fraction With Those With High-Gradient AS
A total of 208 TAVI patients had high-mean gradient 
(MG ≥40 mmHg) severe aortic stenosis (AS) (HG-AS), 85 
had “paradoxical” low-flow, low-gradient PLF-LG (MG ≤40 
mmHg, aortic valve area - AVA ≤0.6 cm2 m−2, stroke volume 
index ≤35 mL/m2, ejection fraction-EF ≥50%), and 61 had 
low-flow low-gradient (LEF-LG; MG ≤40 mmHg, AVA ≤0.6 
cm2 m−2, EF ≤40%). Compared with HG-AS, PLF-LG and 
LEF-LG had higher systemic vascular resistances but lower 
valvulo-arterial impedances. At 30 days, no differences in car-
diac death (~5-6.5%) or death (~6-8.4%) were observed among 
the 3 groups. At 1 year, functional improvement occurred in 
most surviving patients (HG-AS: 69.2% vs. PLF-LG: 71.7% 
vs. LEF-LG: 89.3%, P=0.09) and no significant differences 
in overall  mortality were observed (~17.5-24.5%, P=NS). 
Compared with HG-AS, LEF-LG had a higher 1 year cardiac 
mortality (hazard ratio 2.45, P=0.04). The authors concluded 
that TAVI in PLF-LG or LEF-LG patients is associated with 
overall mortality rates comparable with HG-AS patients and 
all groups have similar benefit (O’Sullivan CJ et al, Eur Heart 
J 2013; 34: 3437-3450).
National Australian Childhood Cardiomyopathy (CM) 
Study: The Highest-Risk Period for Children With 
Dilated CM is in the First Year After Diagnosis (26% 
Compared With ~1% per Year in Subsequent Years)
Among 175 patients 0 to <10 years of age at time of di-
agnosis of dilated cardiomyopathy (DCM), survival free from 
death or transplantation was 74% 1 year after diagnosis, 62% 
at 10 years, and 56% at 20 years. In multivariable analysis, 
age at diagnosis <4 weeks or >5 years, familial CM, and 
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lower baseline left ventricular (LV) systolic function were 
associated with increased risk of death or transplantation. 
At 15 years after diagnosis, echocardiographic normalization 
had occurred in 69% of surviving patients. Children with 
lymphocytic myocarditis had better survival and a higher rate 
of echocardiographic normalization. At the latest follow-up, 
100 of 104 of survivors (96%) were free of cardiac symptoms, 
and 83 (80%) were no longer receiving pharmacotherapy. The 
authors concluded that death or transplantation occurred in 
26% of patients with childhood DCM within 1 year of diag-
nosis and ~1% per year thereafter. Risk factors for death or 
transplantation include age at diagnosis, familial CM, and 
severity of LV dysfunction. The majority of surviving patients 
are well and free of cardiac medication (Alexander PM et al, 
Circulation 2013;128: 2039-2046).
Analysis of 93 801 Procedures of Catheter Ablation of 
Atrial Fibrillation in the United States (2000 – 2010): 
Major Complication Rates Steadily Increasing
An estimated 93,801 AF ablations were performed from 
2000 to 2010 in the US. The overall frequency of in-hospital 
complications was 6.29% with combined cardiac complica-
tions (2.54%) being the most frequent. Cardiac complications 
were followed by vascular (1.53%), respiratory (1.3%), and 
neurological complications (1.02%). The in-hospital mortality 
was 0.46%. Annual operator (<25 procedures) and hospital 
volume (<50 procedures) were significantly associated with 
adverse outcomes. There was a small, albeit non-significant, 
rise in overall complication rates. The authors concluded that 
overall complication rate was 6.29% in patients undergoing AF 
ablation. There was a significant association between operator 
and hospital volume and adverse outcomes (Deshmukh A et 
al, Circulation 2013; 128:2104-2112).
Favorable Effect of a PCSK9 Monoclonal Antibody in 
Homozygous Familial Hypercholesterolemia
A small number (n=8) of patients with homozygous familial 
hypercholesterolemia on stable drug therapy were treated with 
subcutaneous 420 mg Evolocumab/AMG 145 (monoclonal 
antibody to proprotein convertase subtilisin/kexin 9 - PCSK9) 
every 4 weeks for ≥12 weeks, followed by 420 mg every 2 weeks 
for an additional 12 weeks. Mean change from baseline in 
LDL cholesterol at week 12 was −16.5% (P=NS) and −13.9% 
(P=NS) with 4- and 2-week dosing, respectively. No reduc-
tion was seen in the 2 LDL receptor-negative patients. Over 
the treatment periods, mean LDL cholesterol reductions in 
the 6 LDL receptor–defective patients were 19.3±16% and 
26.3±20% with 4- and 2-week dosing, respectively (P=0.03 
for both values). There were no serious side effects. The 
authors concluded that evolocumab produced significant and 
dose-related LDL cholesterol lowering in homozygous familial 
hypercholesterolemia patients with defective LDL receptor 
activity but no reduction in those who were receptor negative 
(Stein EA et al, Circulation 2013;128:2113-2120).
Baseline Mitral Regurgitation Greater Than Mild is 
Associated With Higher Mortality After Corevalve–TAVI
Among 1007 consecutive patients undergoing Corevalve 
transcatheter aortic valve implantation (TAVI), 670 (66.5%) 
had no/mild, 243 (24.1%) moderate, and 94 (9.3%) severe 
mitral regurgitation (MR). At 1 month after TAVI, patients 
with severe or moderate MR showed similar mortality rates, 
but both were higher compared with patients with mild/no MR 
(odds ratio-OR, 2.2 & 1.9, respectively; P<0.05). One-year 
mortality was also similar between patients with severe and 
those with moderate MR (hazard ratio-HR, 1.4; P=0.06) and 
still higher compared with patients with mild/no MR (HR, 1.7; 
P<0.001; & HR, 1.4; P=0.03, respectively). Severe pulmonary 
hypertension, atrial fibrillation (AF), and MR > mild, but not 
an improvement of ≥1 grade in MR severity, were independ-
ent predictors of mortality at 1 year. At 1 year, an improved 
MR was observed in 47% of patients with severe and 35% 
with moderate MR. Functional MR and absence of severe 
pulmonary hypertension and AF independently predicted 
the improvement in MR severity. The authors concluded that 
baseline MR > mild is associated with higher mortality after 
CoreValve–TAVI. A significant improvement in MR was 
more likely in patients with functional MR and without severe 
pulmonary hypertension or AF. The improvement in MR did 
not independently predict mortality (Poli A et al, Circulation 
2013;128:2145-2153).
PARTNER A Trial: Transcatheter Aortic Valve 
Implantation (TAVI) May be a Reasonable Option in 
Select Patients with Concomitant Mitral Valve Disease
Among the PARTNER A trial patients with severe, symp-
tomatic aortic stenosis undergoing either transcatheter (TAVI) 
(n=331) or surgical aortic valve replacement (AVR) (n=299), 
moderate or severe mitral regurgitation (MR) was reported 
at baseline in 65 TAVI patients (19.6%) and 63 surgical pa-
tients (21.2%). At 30 days, among survivors who had isolated 
AVR/TAVI, moderate/severe MR had improved in 25 AVR 
patients (69%) and 30 TAVI patients (58%), was unchanged 
in 10 AVR patients (28%) and 19 TAVI patients (36.5%), and 
worsened in 1 AVR patient (3%) and 4 TAVI patients (6%; 
P=NS). Mortality at 2 years was higher in AVR patients with 
moderate or severe MR than in those with mild or less MR 
(50% vs 28%; hazard ratio-HR, 1.73; P=0.04). In contrast, 
MR severity at baseline did not affect mortality in TAVI pa-
tients (37% vs 33%, moderate/severe vs none/mild; HR, 1.14; 
P=0.58). The authors concluded that both TAVI and AVR 
were associated with a significant early improvement in MR 
in survivors. However, moderate or severe MR at baseline 
was associated with increased 2-year mortality after AVR but 
not after TAVI. TAVI may be a reasonable option in selected 
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patients with concomitant mitral valve disease (Barbanti M et 
al, Circulation 2013;128:2776-2784).
Automated External Defibrillators Inaccessible to 
>50% of Cardiac Arrests in Public Locations During 
Evening, Nighttime, and Weekends
Of 1864 cardiac arrests in public locations in Copenhagen, 
Denmark (1994-2011), 61.8% (n=1152) occurred during the 
evening, nighttime, or weekends. Of 552 registered automated 
external defibrillators (AEDs), 9.1% (n=50) were accessible 
at all hours, and 96.4% (n=532) were accessible during the 
daytime on all weekdays. Regardless of AED accessibility, 
28.8% (537 of 1864) of all cardiac arrests were covered by an 
AED. Limited AED accessibility decreased coverage of cardiac 
arrests by 4.1% (9 of 217) during the daytime on weekdays 
and by 53.4% (171 of 320) during the evening, nighttime, and 
weekends. The authors concluded that limited AED accessibil-
ity at the time of cardiac arrest decreased AED coverage by 
53.4% during the evening, nighttime, and weekends, which is 
when 61.8% of all cardiac arrests in public locations occurred. 
Thus, attention is warranted not only at strategic placement 
but also at uninterrupted AED accessibility, if public-access 
defibrillation is to improve survival after out-of-hospital cardiac 
arrest (Hansen CM et al, Circulation 2013;128:2224-2231).
Patients with Major Bleeding on Dabigatran Managed 
with Supportive Care, Require More Red Cell but Less 
Plasma Transfusions, but Outcomes do not Appear 
Worse than for Warfarin
Bleeding reports were reviewed from 1034 patients with 
1121 major bleeds enrolled in 5 trials comparing dabigatran 
with warfarin in 27,419 patients treated for 6-36 months. Pa-
tients with major bleeds on dabigatran (n=627 of 16,755) were 
older, had lower creatinine clearance, and more frequently 
used aspirin or non-steroid anti-inflammatory agents than 
those on warfarin (n=407 of 10 002). The 30-day mortality 
after the first major bleed tended to be lower in the dabigatran 
group (9.1%) than in the warfarin group (13.0%; P=0.057). 
After adjustment for gender, age, weight, renal function, 
and concomitant antithrombotic therapy, the odds ratio 
for 30-day mortality with dabigatran vs warfarin was 0.66 
(P=0.051). Major bleeds in dabigatran patients required more 
blood transfusions (423/696, 61%) than bleeds in warfarin 
patients (175/425, 42%; P<0.001) but less frequently plasma 
(dabigatran, 19.8%; warfarin, 30.2%; P<0.001). Dabigatran 
patients with a bleed had shorter stay in the intensive care 
unit (mean 1.6 nights) compared with warfarin patients (mean 
2.7 nights; P=0.01). The authors concluded that patients who 
experienced major bleeding on dabigatran required more red 
cell but less plasma transfusions, required a shorter stay in 
intensive care, and had a trend to lower mortality compared 
with those who had major bleeding on warfarin (Majeed A 
et al, Circulation 2013;128:2325-2332).
Active Myocarditis: Left Ventricular Dysfunction at 
Baseline Defines a Subgroup of Patients Characterized 
by Poorer Long-Term Prognosis
From 1981 to 2009, 82 patients with biopsy-proven active 
myocarditis were followed-up for 147±107 months. At baseline, 
left ventricular dysfunction (LVEF <50%) and left atrium en-
largement were independently associated with long-term heart 
transplantation–free survival, regardless of the clinical pattern 
of disease onset. At 6 months, improvement/normalization of 
LVEF was observed in 53% of patients. Persistence of NYHA 
III-IV classes, left atrium enlargement, and improvement/ 
normality of LVEF at 6 months emerged as independent 
predictors of long-term outcome. The authors concluded that 
baseline LV function is a marker for prognosis; its reassessment 
at 6 months appears useful for assessing longer-term outcome 
(Anzini M et al, Circulation 2013;128:2384-2394).
Heart Failure Hospitalization Within 1 Year After 
Acute MI Remains a Marker of High-Risk, With 
Nearly Half of Patients Dying Within a Year After the 
Development of Heart Failure
Among 2 789 943 acute myocardial infarction (AMI) hospi-
talizations of Medicare beneficiaries (1998-2010), the number 
of patients hospitalized for heart failure (HF) within 1 year 
after AMI declined modestly from 16.1 per 100 person-years 
in 1998 to 14.2 per 100 person years in 2010 (P<0.001). After 
adjusting for demographic factors, a relative 14.6% decline for 
HF hospitalizations after AMI was observed. Unadjusted 1-year 
mortality following HF hospitalization after AMI was 44.4% 
in 1998, which decreased to 43.2% in 2004 to 2005, but then 
increased to 45.5% by 2010. After adjusting for demographic 
factors and clinical comorbidities, this represented a 2.4% 
relative annual decline (hazard ratio-HR, 0.976) from 1998 to 
2007, but a 5.1% relative annual increase from 2007 to 2010 
(HR, 1.051). The authors concluded that among Medicare 
beneficiaries, HF hospitalization after AMI decreased by 
~14% from 1998 to 2010, which may indicate improvements 
in the management of AMI. In contrast, survival after HF 
following AMI remains poor, and has worsened (~5%) from 
2007 to 2010, demonstrating that challenges still remain for 
the treatment of this high-risk condition after AMI (Chen J 
et al, Circulation 2013;128:2577-2584).
Hypertophic Cardiomyopathy (HCM): an Abnormal 
High-Sensitivity Cardiac Troponin T (hs-cTnT) is an 
Independent Predictor of Adverse Outcome
Of 183 HCM patients, 99 (54%) had abnormal hs-cTnT 
values (>14 pg/ml). During a mean follow-up of 4.1+2.0 years, 
32 (32%) of these 99 patients, and only 6 (7%) of 84 patients 
with normal hs-cTnT values, experienced cardiovascular (CV) 
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events (CV deaths, heart failure admissions, sustained ventricu-
lar tachycardia, embolic events, and progression to New York 
Heart Association functional class III or IV status) (hazard 
ratio -HR: 5.05, p <0.001). After multivariate analysis, abnor-
mal hs-cTnT value remained an independent predictor of CV 
events (HR: 3.23, p = 0.012). In the abnormal hs-cTnT group, 
overall risk increased with an increase in hs-cTnT value. The 
authors concluded that in patients with HCM, an abnormal 
hs-cTnT is an independent predictor of adverse outcome, and 
a higher degree of abnormality in hs-cTnT value is associated 
with a greater risk of CV events (Kubo T et al, J Am Coll 
Cardiol 2013;62:1252–1259).
MADIT-CRT: in Patients with Mild Heart Failure and 
a CRT-D or ICD Device, Carvedilol Conferred a 36% 
Reduction in Inappropriate ATP and Shock Therapy 
Compared with Patients Receiving Metoprolol
Among patients in the MADIT-CRT study who received a 
cardiac resynchronization therapy (CRT) defibrillator (CRT-
D) or an implantable cardioverter-defibrillator (ICD) device 
(N=1790), inappropriate therapy occurred in 253 (14%) over 
3.4±1.1 years. Treatment with carvedilol was associated with 
a significantly decreased risk of inappropriate therapy (anti-
tachycardia pacing-ATP or shock) compared with metoprolol 
(hazard ratio - HR: 0.64; p = 0.002). The risk of inappropriate 
therapy caused by atrial fibrillation was also reduced in patients 
receiving carvedilol compared with metoprolol (HR: 0.50; p 
= 0.004). The authors concluded that in heart failure patients 
receiving a CRT-D or an ICD device, carvedilol was associated 
with a 36% lower rate of inappropriate ATP and shock therapy 
compared with metoprolol. Inappropriate therapy due to atrial 
fibrillation was associated with a 50% lower rate in patients 
receiving carvedilol compared with those receiving metoprolol 
(Ruwald MH et al, J Am Coll Cardiol 2013;62:1343–1350).
Meta-Analysis of 5 Cardiac Resynchronization Therapy 
(CRT) Trials Confirmed Benefit in Heart Failure (HF) 
Patients in Sinus Rhythm & QRS >140 ms
Per a meta-analysis of 5 randomized trials comparing CRT 
with no active control (CARE-HF, MIRACLE, REVERSE) 
or CRT-D with ICD (REVERSE, MIRACLE ICD, RAFT), 
3782 of 4317 patients were in sinus rhythm, with median age 
66 years, QRS duration 160 ms, LVEF 24%, and left bundle 
branch block in 78%. Per multivariate analysis, only QRS 
duration predicted the magnitude of the effect of CRT on 
outcomes. There was an increasing benefit with increasing 
QRS duration, and a high probability of substantial benefit 
from CRT when QRS duration exceeds 140 ms. The authors 
concluded that QRS duration is a powerful predictor of the 
effects of CRT on morbidity and mortality in patients with 
symptomatic HF and LV systolic dysfunction who are in sinus 
rhythm (Cleland JG et al, Eur Heart J 2013; 34: 3547–3556).
EchoCRT Study: Cardiac-Resynchronization Therapy 
(CRT) in Heart Failure (HF) with a Narrow QRS 
Offers no Benefit and may Increase Mortality
A total of 809 patients with NYHA class III or IV HF, ejec-
tion fraction of ≤35%, a QRS <130 ms, and echocardiographic 
evidence of LV dyssynchrony were randomly assigned to have 
CRT on or off. On March 13, 2013, the study was stopped for 
futility; mean follow-up was 19.4 months. The primary outcome 
(death or first hospitalization for worsening HF) occurred in 
116 of 404 patients (28.7%) in the CRT group, as compared 
with 102 of 405 in the control group (25.2%) (hazard ratio-HR, 
1.20; P=0.15). There were 45 deaths in the CRT group (11.1%) 
and 26 in the control group (6.4%) (HR, 1.81; P=0.02). The 
authors concluded that in patients with HF and a QRS <130 
ms, CRT does not reduce the rate of death or hospitalization 
for HF and may increase mortality (Ruschitzka F et al, N Engl 
J Med 2013; 369:1395-1405).
Meta-analysis of 18 Trials: Aspiration Thrombectomy 
During AMI is Beneficial in Reducing MACE and 
Mortality at 6-12 Months Compared with Conventional 
PCI Alone
Acute myocardial infarction (AMI) patients randomized 
to aspiration (18 trials, n=3,936) or mechanical thrombectomy 
(7 trials, n=1,598) before PCI were compared with conven-
tional PCI alone. At mean 6-month follow-up, major adverse 
cardiac events (MACE) (risk ratio -RR: 0.76; p = 0.006) and 
all-cause mortality (RR: 0.71; p = 0.049) were significantly 
reduced with aspiration thrombectomy. Beneficial trends were 
noted for recurrent MI (p = 0.11) and target vessel revascu-
larization (p = 0.06). Final infarct size and ejection fraction 
at 1 month were similar. ST resolution at 60 min (RR: 1.31; p 
<0.0001) and TIMI blush grade 3 post-procedure (RR: 1.37; p 
<0.0001) were both improved with aspiration thrombectomy. 
In contrast, there was no difference in almost all end-points 
with mechanical thrombectomy vs. conventional primary PCI 
(7 trials, n = 1,598). The authors concluded that in AMI, 
manual, but not mechanical, catheter aspiration, is beneficial 
in reducing mortality and MACE at 6-12 months compared 
with conventional primary PCI alone (Kumbhani DJ et al, J 
Am Coll Cardiol 2013;62:1409–1418).
EMPHASIS-HF Study: Eplerenone Appears Safe and 
Efficacious in Patients with Heart Failure at High Risk 
for Hyperkalemia and/or Worsening Renal Function
Heart failure (HF) patients at high risk for hyperkalemia 
or worsening renal function (WRF) in the EMPHASIS-HF 
trial, i.e. patients older than 75, with diabetes, estimated 
glomerular filtration rate (eGFR) <60 ml/min/1.73 m2, and 
relatively low systolic blood pressure, but with eGFR >30 
ml/min/1.73 m2 and serum potassium <5.0 mmol/l received 
eplerenone. These high-risk patient subgroups treated with 
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eplerenone had an increased risk of potassium >5.5 mmol/l 
but not of potassium >6.0 mmol/l, and of hospitalization for 
hyperkalemia or discontinuation of study medication due to ad-
verse events. Eplerenone was effective in reducing the primary 
endpoint (hospitalization for HF or cardiovascular mortality) 
in all subgroups. The authors concluded that eplerenone was 
both efficacious and safe when carefully monitored, even in 
subgroups at high risk of developing hyperkalemia or WRF 
(Eschalier R et al, J Am Coll Cardiol 2013;62:1585–1593).
ALTITUDE Study: In ICD or CRT-D Patients Adverse 
Prognosis after Shock Therapy is Related to Under-
lying Arrhythmia (VT/AF) and not to the Shock Itself
Comparing patients (n=3,809) with first shock with patients 
without a shock (n=3,630), there was an increased rate of mor-
tality in those who received their first shock for monomorphic 
ventricular tachycardia (hazard ratio - HR: 1.65, p <0.0001), 
ventricular fibrillation/polymorphic ventricular tachycardia 
(HR: 2.10, p <0.0001), and atrial fibrillation/flutter (HR: 1.61, 
p = 0.003). In contrast, mortality after first shocks due to sinus 
tachycardia and supraventricular tachycardia (HR: 0.97, p = 
NS) and noise/artifact/oversensing (HR: 0.91, p = NS) was 
comparable to that in patients without a shock. The authors 
concluded that compared with no shock, those who received 
their first shock for ventricular rhythms and atrial fibrillation 
had an increased risk of death with no difference noted for 
shocks due to sinus tachycardia or noise/artifact/oversensing 
(Powell BD et al, J Am Coll Cardiol 2013;62:1674–1679).
Wearable Cardioverter-Defibrillator Protects High-
Risk Patients Early Post-Myocardial Infarction while 
Waiting for an ICD
For the mandatory ICD implantation waiting time post-
myocardial infarction (MI) of either 40 days or 3 months (for 
those revascularized), a wearable cardioverter-defibrillator 
(WCD) was provided in 8453 patients (2005-2011). A total 
of 133 patients (1.6%) received 309 appropriate shocks. Of 
these patients, 91% were resuscitated from a ventricular ar-
rhythmia. For shocked patients, the left ventricular ejection 
fraction (LVEF) was ≤30% in 106, 30-35% in 17, >36% in 
8, and not reported in 2 patients. Of the 38% of patients not 
revascularized, 84% had a LVEF ≤30%; of the 62% of pa-
tients revascularized, 77% had a LVEF ≤30%. The median 
time from the index MI to WCD therapy was 16 days. Of the 
treated patients, 75% received a shock in the first month, and 
96% within the first 3 months of use. Shock success resulting in 
survival was 84% in nonrevascularized and 95% in revascular-
ized patients. The authors concluded that during the 40-day 
and 3-month waiting periods in patients post-MI, the WCD 
successfully treated sudden cardiac arrest in 1.4%, and the risk 
was highest in the first month of WCD use (Epstein AE et al, 
J Am Coll Cardiol 2013;62:2000–2007).
Non-Receivers of Pre-Procedural Aspirin are More 
Likely to Experience Adverse Outcomes of PCI (Higher 
Rate of In-Hospital Death and Stroke)
Among 65,175 patients, 4640 (7.1%) did not receive aspirin 
within 24 h before undergoing PCI. Aspirin non-receivers were 
more likely to have had previous gastrointestinal bleeding 
or to present with cardiogenic shock or after cardiac arrest. 
Absence of aspirin before PCI was associated with a higher 
rate of death (3.9% vs. 2.8%; odds ratio-OR: 1.89, p <0.001) 
and stroke (0.5% vs. 0.1%; OR: 4.24, p = 0.007) with no dif-
ference in need for transfusions. The authors concluded that 
a significant number of patients do not receive aspirin before 
undergoing PCI. Lack of aspirin before PCI was associated 
with increased in-hospital mortality and stroke (Kenaan M et 
al, J Am Coll Cardiol 2013;62:2083–2089).
Added Autonomic Denervation Enhances Pulmonary 
Vein Isolation (PVI) for Paroxysmal Atrial Fibrillation
A total of 242 patients with paroxysmal atrial fibrillation 
(PAF) were randomized to PVI (n=78), ablation of the left 
atrial ganglionated plexi (GP) (n=82); or PVI+GP ablation 
(n=82). Freedom from PAF or atrial tachycardia (AT) was 
achieved in 44 (56%), 39 (48%), and 61 (74%) patients in 
the PVI, GP, and PVI+GP groups, respectively (p=0.004). 
PVI+GP ablation compared with PVI alone was better (hazard 
ratio of 0.53; p=0.022). Fluoroscopy duration was 16+3 min, 
20+5 min, and 23±5 min for PVI, GP, and PVI+GP groups, 
respectively (p<0.001). Post-ablation atrial flutter was similar 
among groups (5-6%). No serious complications were reported. 
The authors concluded that addition of GP ablation to PVI 
confers a significantly higher success rate compared with either 
PVI or GP alone in patients with PAF (Katritsis D et al, J Am 
Coll Cardiol 2013;62:2318–2325).
Relax-AHF Trial: Consistent Effects of Serelaxin 
Across All Subgroups of Patients With Acute Heart 
Failure
The RELAX-AHF trial included 1161 patients (placebo, 
n = 580; serelaxin, n = 581). Subgroup analyses did not show 
any difference in the effects of serelaxin vs. placebo on dyspnea 
relief or on the incidence of cardiovascular death or rehospitali-
zations for heart failure or renal failure at 60 days. The authors 
concluded that subgroup analyses of the RELAX-AHF trial 
has shown similar effects of serelaxin, when compared with 
placebo, across various subgroups, suggesting a consistency of 
the effect of serelaxin in the patients with acute heart failure 
(Metra M et al, Eur Heart J 2013; 34, 3128–3136).
ORIGIN trial: Hypoglycemia Increases the Risk of 
Cardiovascular Events
A total of 12,537 patients with dysglycemia and high cardio-
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vascular (CV) risk were randomized to basal insulin glargine 
titrated to a fasting glucose of ≤5.3 mmol/L (95 mg/dL) or 
standard glycemic care. Non-severe hypoglycemia was defined 
as symptoms plus glucose ≤54 mg/dL and severe hypoglycemia 
if required assistance or glucose ≤36 mg/dL. During a median 
of 6.2 years, non-severe hypoglycemic episodes occurred in 
41.7% of glargine and 14.4% of standard care patients, while 
severe episodes occurred in 5.7% and 1.8%, respectively. 
Only severe hypoglycemia was associated with a greater risk 
for the primary outcome (CV death, MI or stroke) (HR: 1.58, 
P <0.001), mortality (HR: 1.74; P <0.001), CV death (HR: 
1.71; P <0.001) and arrhythmic death (HR: 1.77; P = 0.007). 
Similar findings were noted for severe nocturnal hypoglycemia 
for the primary outcome and mortality. The authors concluded 
that severe hypoglycemia is associated with an increased risk 
for CV outcomes in people at high CV risk and dysglycemia. 
Although the glargine group had an increased risk of hypo-
glycemia, the relative risk of CV outcomes with hypoglycemia 
was lower with insulin glargine-based therapy than with the 
standard glycemic control (ORIGIN Trial Investigators, Eur 
Heart J 2013; 34, 3137–3144).
Meta-Analysis: Patent Foramen Ovale Transcatheter 
Closure Superior to Medical Therapy on Recurrent 
Vascular Events Over a Mean Follow-up of 3.5 Years
A meta-analysis was performed of 3 randomized stud-
ies (PC, CLOSURE I, and RESPECT trials) (N= 2,303) of 
transcatheter (TC) closure of a patent foramen ovale (PFO) 
(n=1150) vs medical therapy (n= 1,153) in patients with 
cryptogenic stroke. Mean follow-up was 3.5 years. Baseline 
characteristics were similar across studies. Intention-to-treat 
analyses showed a statistically significant risk reduction in 
stroke and/or transient ischemic attack in the TC PFO closure 
group when compared to medical treatment (pooled HR=0.59, 
P=0.04). The combined outcome of death, and vascular 
events, showed a borderline benefit for TC PFO closure when 
compared to medical treatment (HR=0.67, P=0.05). Subjects 
with a substantial PFO shunt tend to benefit the most with TC 
PFO closure (HR=0.35, P=0.06) (Rengifo-Moreno P et al, 
Eur Heart J 2013; 34, 3342–3352).
Randomized Trial Comparing 3 Different Devices 
For Percutaneous Closure of a Patent Foramen Ovale 
(PFO): Significant Differences in the Neurological 
Event Rate Among Devices
PFO closure was technically successful in all 660 patients 
with cryptogenic stroke randomized to 3 different closure 
devices (Amplatzer, CardioSEAL-STARflex, and Helex oc-
cluder, n=220 per group). The procedure was complicated 
by cardiac tamponade requiring surgery in 1 (Amplatzer 
group) and device embolization in 3 patients (Helex group). 
Thrombus formation on the device was detected in 12 cases (11 
CardioSEAL-STARflex, 1 Helex, 0 Amplatzer; P <0.0001), of 
which 2 required surgery. Complete closure after single device 
implantation was more common with the Amplatzer and with 
the CardioSEAL-STARflex than with the Helex occluder. 
Within 5 years of follow-up, the primary endpoint (recurrent 
cerebral ischemia, i.e. stroke, transient ischemic attacks-TIA, 
or amaurosis fugax; death from neurological cause; or any 
other paradoxical embolism) occurred in 25 patients (3.8%; 
10 TIAs, 12 strokes and 3 cases of cerebral death). Compared 
with the CardioSEAL-STARflex (6%; 6 TIAs, 6 strokes, 1 
cerebral death) and Helex groups (4%; 4 TIAs, 4 stroke, 1 
cerebral death), significantly fewer events (P=0.04) occurred 
in the Amplatzer group (1.4%; 2 strokes, 1 cerebral death). 
The authors concluded that procedural complications and 
long-term neurological event rates are low regardless of de-
vice used; however, the recurrent neurological event rate was 
significantly lower after Amplatzer implantation (Hornung M 
et al, Eur Heart J 2013; 34:3362–3369).
Vascular Closure Devices Largely Reduce Vascular 
Complications Over Manual Closure Among Patients 
Having Percutaneous Coronary Intervention
Of the 85,048 percutaneous coronary interventions (PCIs) 
performed in 32 hospitals in Michigan (2007-2009), 28,528 
(37%) procedures used vascular closure devices (VCDs). VCDs 
were associated with reductions in vascular complications (odds 
ratio-OR, 0.78; P=0.001) and postprocedure transfusions (OR, 
0.85; P=0.011), except in patients with a body mass index 
(BMI) <25 kg/m2 and those treated with platelet glycoprotein 
(GP) IIb/IIIa inhibitors. VCDs were associated with fewer 
hematomas (OR, 0.69; P<0.001) or pseudoaneurysms (OR, 
0.54; P<0.001) but an increase in the odds of retroperitoneal 
bleeding (OR, 1.57; P=0.009). The authors concluded that 
VCDs were associated with a significant reduction in vascular 
complications and need for transfusion, albeit with no benefit 
when GP IIb/IIIa inhibitors were used and in those with normal 
or lean BMI; there was a small increase in the more serious 
risk for retroperitoneal bleeding (Gurm HS et al, Ann Intern 
Med 2013;159:660-666).
Atrial Ectopy is a Predictor of Incident Atrial Fibrillation
In 1260 adults without atrial fibrillation (AF) enrolled in 
the Cardiovascular Health Study (1989-1990), the premature 
atrial contraction (PAC) count was quantified by 24-hour Holter 
monitor. Doubling of the hourly PAC count was associated 
with a significant increase in AF risk (hazard ratio-HR, 1.17; 
P<0.001) and overall mortality (HR, 1.06; P<0.001). Compared 
with the Framingham model, PAC count alone resulted in 
similar AF risk discrimination at 5 and 10 years of follow-up 
and superior risk discrimination at 15 years. The addition of 
PAC count to the Framingham model resulted in significant 
10-year AF risk discrimination improvement. The specificity 
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for predicting AF at 15 years was >90% for PAC counts over 
32 beats/h. The authors concluded that the addition of PAC 
count to a validated AF risk algorithm provides superior AF 
risk discrimination and significantly improves risk reclassifica-
tion (Dewland TA eta l, Ann Intern Med 2013;159:721-728).
SAVOR-TIMI 53 & EXAMINE Trials: the New 
Dipeptidyl Peptidase 4 (DPP-4) Inhibitors, Saxagliptin 
and Alogliptin, May not Have Serious Adverse 
Cardiovascular (CV) Effects
In the SAVOR-TIMI 53 study, 16,492 patients with type 
2 diabetes with history of, or at risk for, CV events were ran-
domly assigned to receive saxagliptin or placebo. At 2 years, 
a primary end-point event (CV death, myocardial infarction-
MI, or ischemic stroke) occurred in 613 patients (7.3%) in 
the saxagliptin group and in 609 patients in the placebo group 
(7.2%) (P=NS) The major secondary end point (CV death, MI, 
stroke, hospitalization for unstable angina, coronary revascu-
larization, or heart failure) occurred in 1059 patients (12.8%) 
in the saxagliptin group and in 1034 patients in the placebo 
group (12.4%) (P=NS). More patients in the saxagliptin group 
(3.5%) than in the placebo group (2.8%) were hospitalized 
for heart failure (hazard ratio-HR, 1.27; P=0.007). Rates of 
pancreatitis were similar in the two groups (acute pancreatitis, 
0.3% in the saxagliptin group and 0.2% in the placebo group; 
chronic pancreatitis, <0.1% and 0.1% in the two groups, 
respectively). The authors concluded that saxagliptin did not 
increase or decrease the rate of ischemic events, though the 
rate of hospitalization for heart failure was increased (Scirica 
BM et al, N Engl J Med 2013; 369:1317-1326).
In the EXAMINE study, a total of 5380 patients with type 
2 diabetes and either an acute MI or unstable angina within 
previous 15-90 days underwent randomization to alogliptin or 
placebo and were followed for up to 40 months (median, 18 
months). A primary end-point event (CV death, MI or stroke) 
occurred in 305 patients assigned to alogliptin (11.3%) and in 
316 patients assigned to placebo (11.8%) (HR, 0.96). Glycated 
hemoglobin levels were significantly lower with alogliptin 
than with placebo (mean difference, −0.36 percentage points; 
P<0.001). Incidences of hypoglycemia, cancer, pancreatitis, 
and initiation of dialysis were similar with alogliptin and pla-
cebo. The authors concluded that among patients with type 2 
diabetes who had had a recent acute coronary syndrome, the 
rates of major adverse cardiovascular events were not increased 
with the DPP-4 inhibitor alogliptin as compared with placebo 
(White WB et al, N Engl J Med 2013; 369:1327-1335).
Hokusai-VTE Study: Edoxaban is Noninferior to 
Warfarin for the Treatment of Symptomatic Venous 
Thromboembolism and Causes Less Bleeding
Patients with deep venous thrombosis (n=4921) or pul-
monary embolism (n=3319), initially receiving heparin, were 
randomized to edoxaban at a dose of 60 mg or 30 mg (if 
creatinine clearance 30-50 ml/min or if weight <60 kg) once 
daily, or warfarin for 3-12 months. Among patients receiv-
ing warfarin, the time in the therapeutic range was 63.5%. 
Edoxaban was noninferior to warfarin; the primary efficacy 
outcome (recurrent symptomatic venous thromboembolism) 
occurred in 130 patients in the edoxaban group (3.2%) and 146 
patients in the warfarin group (3.5%) (hazard ratio-HR, 0.89; 
P<0.001 for noninferiority). The safety outcome (major or 
clinically relevant nonmajor bleeding) occurred in 349 patients 
(8.5%) in the edoxaban group and 423 patients (10.3%) in the 
warfarin group (HR, 0.81; P=0.004 for superiority). The rates 
of other adverse events were similar. A total of 938 patients 
with pulmonary embolism had right ventricular dysfunction, 
as assessed by measurement of N-T pro-BNP levels; the rate 
of recurrent venous thromboembolism in this subgroup was 
3.3% in the edoxaban group and 6.2% in the warfarin group 
(HR, 0.52). The authors concluded that edoxaban once daily 
after initial treatment with heparin was noninferior to stand-
ard therapy and caused significantly less bleeding in patients 
with venous thromboembolism, including those with severe 
pulmonary embolism (The Hokusai-VTE Investigators, N 
Engl J Med 2013; 369:1406-1415).
ENGAGE AF-TIMI 48 Trial: in Patients with Atrial 
Fibrillation, Edoxaban was Equivalent to Warfarin for 
Prevention of Thromboembolism but Had Lower Rates 
of Bleeding and Cardiovascular (CV) Death
A total of 21,105 patients with moderate-to-high-risk 
atrial fibrillation (AF) were randomized to edoxaban, a direct 
oral factor Xa inhibitor (2 once daily regimens) or warfarin. 
At median follow-up of 2.8 years, the annualized rate of the 
primary end point (stroke or systemic embolism) was 1.50% 
with warfarin (median time in the therapeutic range, 68.4%), 
compared with 1.18% with high-dose edoxaban (hazard ra-
tio-HR, 0.79; P<0.001 for noninferiority) and 1.61% with 
low-dose edoxaban (HR, 1.07; P=0.005 for noninferiority). 
In the intention-to-treat analysis, there was a trend favoring 
high-dose edoxaban vs warfarin (HR, 0.87; P=0.08) and an 
unfavorable trend with low-dose edoxaban vs warfarin (HR, 
1.13; P=0.10). The annualized rate of major bleeding was 
3.43% with warfarin vs 2.75% with high-dose edoxaban (HR, 
0.80; P<0.001) and 1.61% with low-dose edoxaban (HR, 0.47; 
P<0.001). The respective annualized rates of death from CV 
causes were 3.17% vs 2.74% (HR, 0.86; P=0.01), and 2.71% 
(HR, 0.85; P=0.008), and rates of the key secondary end point 
(a composite of stroke, systemic embolism, or death from CV 
causes) were 4.43% vs 3.85% (HR, 0.87; P=0.005), and 4.23% 
(HR, 0.95; P=0.32). The authors concluded that both once-daily 
regimens of edoxaban were noninferior to warfarin for preven-
tion of stroke or systemic embolism and were associated with 
significantly lower rates of bleeding and CV death (Giugliano 
RP et al, N Engl J Med 2013; 369:2093-2104).
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EUROMAX: Bivalirudin Started During Transport for 
Primary PCI, at 30 Days Reduced Major Bleeding but 
Increased Acute Stent Thrombosis
A total of 2218 patients with STEMI transported for primary 
PCI were randomly assigned to receive either bivalirudin or 
unfractionated or low-molecular-weight heparin with optional 
glycoprotein IIb/IIIa inhibitors (control group). Bivalirudin 
reduced the risk of the primary outcome at 30 days (death 
or major bleeding) (5.1% vs. 8.5%; relative risk-RR, 0.60; 
P=0.001) and secondary outcome (death, reinfarction or non-
CABG major bleeding) (6.6% vs. 9.2%; RR, 0.72; P=0.02). 
Bivalirudin also reduced the risk of major bleeding (2.6% vs. 
6.0%; RR, 0.43; P<0.001). The risk of acute stent thrombosis 
was higher with bivalirudin (1.1% vs. 0.2%; RR, 6.11; P=0.007). 
There was no significant difference in rates of death (~3%) 
or reinfarction (1.7% vs. 0.9%). The authors concluded that 
bivalirudin, started during transport for primary PCI, improved 
30-day clinical outcomes with a reduction in major bleeding 
but with an increase in acute stent thrombosis (Steg PG et al, 
N Engl J Med 2013; 369:2207-2217).
ICAP Study: Added Colchicine Therapy Reduces Rate 
of Incessant or Recurrent Pericarditis
A total of 240 patients with acute pericarditis were randomly 
assigned to receive colchicine (0.5 mg bid for 3 months if weight 
>70 kg or 0.5 mg qd if weight ≤70 kg) or placebo in addition to 
conventional antiinflammatory therapy with aspirin or ibupro-
fen. The primary outcome (incessant or recurrent pericarditis) 
occurred in 20 patients (16.7%) in the colchicine group and 
45 patients (37.5%) in the placebo group (relative risk reduc-
tion, 0.56; number needed to treat, 4; P<0.001). Colchicine 
reduced the rate of symptom persistence at 72 hours (19.2% 
vs. 40.0%, P=0.001), the number of recurrences per patient 
(0.21 vs. 0.52, P=0.001), and the hospitalization rate (5.0% vs. 
14.2%, P=0.02). Colchicine also improved the remission rate 
at 1 week (85.0% vs. 58.3%, P<0.001). Overall adverse effects 
and rates of study-drug discontinuation were similar. No seri-
ous adverse events were observed. The authors concluded that 
in patients with acute pericarditis, colchicine, when added to 
conventional antiinflammatory therapy, significantly reduced 
the rate of incessant or recurrent pericarditis (Imazio M et al, 
N Engl J Med 2013; 369:1522-1528).
Meta-Analysis: Influenza Vaccination Prevents 
Cardiovascular (CV) Events in High-Risk Patients
A total of 6 randomized trials were analyzed (N=6735; 
mean age, 67 years; 51.3% women; 36.2% with a cardiac history; 
mean follow-up, 7.9 months), comparing influenza vaccine vs 
placebo or control, stratified by subgroups of patients with and 
without a history of acute coronary syndrome (ACS) within 1 
year of randomization. Influenza vaccine was associated with 
a lower risk of composite CV events (2.9% vs 4.7%; relative 
risk-RR, 0.64, P =0 .003). A treatment interaction was detected 
between patients with (RR, 0.45) and without (RR, 0.94) recent 
ACS (P for interaction = 0.02). The authors concluded that 
the use of influenza vaccine was associated with a lower risk 
of major adverse cCV events. The greatest treatment effect 
was seen among the highest-risk patients with more active 
coronary disease (Udell JA et al, JAMA 2013;310:1711-1720).
Dose-Dependent Inverse Association Between Nut 
Consumption and Total Mortality & Major Causes of 
Death (Heart Disease/ Cancer/ Respiratory Diseases)
The association between nut consumption and total and 
cause-specific mortality was examined among 76,464 women 
in the Nurses’ Health Study (1980–2010) and 42,498 men in 
the Health Professionals Follow-up Study (1986–2010). Dur-
ing 3,038,853 person-years of follow-up, 16,200 women and 
11,229 men died. Nut consumption was inversely associated 
with total mortality among both women and men and was 
dose-dependent (best hazard ratio 0.80 for those who ate nuts 
>7 times per week; P<0.001 for trend). Significant inverse as-
sociations were also observed between nut consumption and 
deaths due to cancer, heart disease, and respiratory disease. 
The authors concluded that the frequency of nut consumption 
was inversely associated with total and cause-specific mortal-
ity, independently of other predictors of death (Bao Y et al, 
N Engl J Med 2013;369:2001-2011).
IABP-SHOCK II Trial: In Patients with Acute MI & 
Cardiogenic Shock Undergoing Revascularization, 
IABP did not Reduce 12-Month Mortality
In the initial IABP-SHOCK II trial, the intra-aortic balloon 
pump (IABP) did not reduce 30 day mortality compared with 
control. Follow-up was continued for 12 months. A total of 600 
patients with cardiogenic shock complicating acute myocardial 
infarction (MI) who were undergoing early revascularization 
were assigned to IABP (n=301) or control (n=299). Of 595 
patients completing 12 month follow-up, 155 (52%) of 299 
patients in the IABP group and 152 (51%) of 296 patients in 
the control group had died (relative risk -RR 1·01, p=NS). 
There were no significant differences in reinfarction (RR 
2.60, p=0.05), recurrent revascularization (0.91, p=0.77), or 
stroke (1.50, p=NS). The authors concluded that in patients 
undergoing early revascularization for MI complicated by 
cardiogenic shock, IABP did not reduce 12 month all-cause 
mortality (Thiele H et al, The Lancet; 382(9905):1638 – 1645).
CHAMPION Pooled Analysis: Cangrelor Reduced PCI 
Periprocedural Thrombotic Complications,  
at the Expense of Increased Bleeding
Pooled analysis of data from 3 trials (CHAMPION-PCI 
/ CHAMPION-PLATFORM/ CHAMPION-PHOENIX) 
comparing cangrelor with control (clopidogrel or placebo) for 
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prevention of thrombotic complications during and after PCI, 
included 24,910 patients undergoing PCI for STEMI (11.6%), 
non-ST-elevation acute coronary syndromes (ACS) (57.4%), 
and stable coronary artery disease (31%). Cangrelor reduced 
the primary outcome (death, MI, ischemia-driven revasculariza-
tion, or stent thrombosis at 48 h) by 19% (3.8% for cangrelor 
vs 4.7% for control; odds ratio -OR 0.81, p=0.0007), and 
stent thrombosis by 41% (0.5% vs 0.8%, OR 0.59, p=0.0008). 
Benefits were maintained at 30 days. There was no difference 
in the primary safety outcome (severe bleeding) (0.2% in both 
groups), moderate bleeding (0.6% vs 0.4%), or in transfusion 
(0.7% vs 0.6%), but cangrelor increased mild bleeding (16.8% 
vs 13%, p<0.0001). The authors concluded that cangrelor 
reduced PCI periprocedural thrombotic complications, at the 
expense of increased bleeding (Steg PG et al, Lancet 2013; 
382(9909):1981-1992).
Important Review and Other Articles
Coronary artery revascularization in patients with diabe-
tes (Armstrong EJ, et al, Circulation 2013; 128:1675-1685), 
Obesity in children & adolescents (Kelly AS, et al, Circulation 
2013; 128:1689-1712), Childhood obesity and cardiovascular 
dysfunction (Cote AT et al, J Am Coll Cardiol 2013;62:1309-
1319), 2013 ACCF/AHA Guideline for management of heart 
failure (Clyde WY et al, Circulation 2013;128:e240-e327; J 
Am Coll Cardiol 2013;62:e147-e239), Antithrombotic therapy 
during and after PCI in patients with AF (Verheugt FW, 
Circulation 2013;128:2058-2061), ICD leads (Swerdlow CD 
& Ellenbogen KA, Circulation 2013;128:2062-2071), Renal 
denervation therapy for hypertension (Thukkani AK & Bhatt 
DL, Circulation 2013;128: 2251-2254;& Schlaich MP et al, 
J Am Coll Cardiol 2013,62:2031-2045), Peripheral arterial 
disease (Wennberg PW, Circulation 2013;128:2241-2250), 
Vitamin D and cardiovascular health (Lavie CJ et al, Circula-
tion 2013;128:2404-2406), Cardiac resynchronization therapy 
(Prinzen FW et al, Circulation 2013;128:2407-2418), Role 
of vitamin D in atherosclerosis (Kassi E et al, Circulation 
2013;128:2517-2531), Pulseless electric activity (Myerburg 
RJ et al, Circulation 2013;128:2532-2541), Effects of external 
electrical and magnetic fields on pacemakers and defibril-
lators (Beinart R & Nazarian S, Circulation 2013;128:2799-
2809), Managing antiplatelet therapy in coronary patients 
requiring surgery (Capodanno D & Angiolillo DJ, Circulation 
2013;128:2785-2798), Targeting the PCSK9 for treatment of 
dyslipidemia (Urban et al, J Am Coll Cardiol. 2013;62:1401-
1408), Treatment of obstructive thrombosed prosthetic 
heart valve (Huang G et al, J Am Coll Cardiol 2013;62:1731-
1736), Colchicine and the heart (Deftereos S et al, J Am Coll 
Cardiol 2013;62:1817-1825), the MOGE(S) nomenclature 
system for cardiomyopathies (Arbustini E et al, J Am Coll 
Cardiol 2013;62:2046-2072), Antithrombotic treatment in TAVI 
(Rodés-Cabau J et al, J Am Coll Cardiol 2013;62:2349-2359), 
Pulmonary hypertension (J Am Coll Cardiol December 24, 
2013, Vol. 62, No. 25_S), 2013 ESC guidelines on the manage-
ment of stable coronary artery disease (Montalescot G et al, 
Eur Heart J 2013;34: 2949-3003), ESC/EASD Guidelines on 
diabetes, pre-diabetes, and cardiovascular diseases (Rydén L, 
Eur Heart J 2013; 34:3035-3087), Long QT syndrome (Schwartz 
PJ & Ackerman MJ, Eur Heart J 2013; 34: 3109-3116), Stabi-
lization of atherosclerotic plaques (Ylä-Herttuala S et al, Eur 
Heart J 2013; 34: 3251-3258), Brugada syndrome (Brugada et 
al, Eur Heart J 2013; 34: 3610-3615), Management of obstruc-
tive sleep apnea (Qaseem A et al, Ann Intern Medicine 2013; 
159:471-483), Screening for primary hypertension in children 
and adolescents (Moyer VA et al, Ann Intern Medicine 2013; 
159:613-619), Statins & cognitive function (Richardson K et al, 
Ann Intern Medicine 2013; 159:688-697), Treatment of anemia 
in heart disease (Quaseem A et al, Ann Intern Medicine 2013; 
159:770-779; & Kansagara T et al, Ann Intern Medicine 2013; 
159:746-757), Circulatory shock (Vincent J-L & De Backer D, 
N Engl J Med 2013; 369:1726-1734), β-blockers for hyperten-
sion (Wiysonge CS & Opie LH, JAMA 2013; 310:1851-1852), 
Inherited primary arrhythmia syndromes (Priori SG et al, Heart 
Rhythm 2013; 10: 1932-1963).
